NCT02489344View on ClinicalTrials.gov

Evaluation of the Long-term Safety, Pharmacodynamics, and Exploratory Efficacy of GZ/SAR402671 in Treatment-Naïve Adult Male Patients With Fabry Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

July 7, 2015

Primary Completion Date

November 20, 2018

Study Completion Date

November 20, 2018

Conditions
Fabry Disease
Interventions
DRUG

GZ/SAR402671

"Pharmaceutical form:capsule~Route of administration: oral"

Trial Locations (7)

22030

Investigational Site Number 840001, Fairfax

30322

Investigational Site Number 840002, Atlanta

45229

Investigational Site Number 840003, Cincinnati

92380

Investigational Site Number 250001, Garches

125167

Investigational Site Number 643002, Moscow

04-730

Investigational Site Number 616001, Warsaw

CB2 OQQ

Investigational Site Number 826002, Cambridge

All Listed Sponsors
lead

Genzyme, a Sanofi Company

INDUSTRY

NCT02489344 - Evaluation of the Long-term Safety, Pharmacodynamics, and Exploratory Efficacy of GZ/SAR402671 in Treatment-Naïve Adult Male Patients With Fabry Disease | Biotech Hunter | Biotech Hunter